MediGene genital warts study fully-enrolled
German biopharmaceutical company MediGene has completed recruitment in aPhase III trial of its Polyphenon E product in patients with genital warts and says it expects to report results from the study by the end of the year. The aim of the trial will be to look at two different formulations of Polyphenon, a mixture of polyphenols which have been shown to inhibit human papillomavirus, the causative agent in genital warts.
Peter Heinrich, MediGene's chief executive, said that the company hopes to bring the product to market in 2003. He added that analysts have predicted peak sales potential of 50 million euros ($44 million) for "innovative treatments like...Polyphenon E."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze